EMBARGOED FOR RELEASE: 3 P.M. (CT), THURSDAY, AUGUST 21, 2014
Media Advisory: To contact author Uchechukwu C. Megwalu, M.D., M.P.H., call Sid Dinsay at 212-241-9200 or email firstname.lastname@example.org.
To place an electronic embedded link to this study in your story The link for this study will be live at the embargo time: http://archotol.jamanetwork.com/article.aspx?doi=10.1001/jamaoto.2014.1671.
JAMA Otolaryngology-Head & Neck Surgery
Bottom Line: Patients with advanced laryngeal cancer appear to have better survival if they are treated with surgery than nonsurgical chemoradiation.
Author: Uchechukwu C. Megwalu, M.D., M.P.H., of the Ichan School of Medicine at Mount Sinai, New York, and colleagues.
Background: Approximately 11,000 to 13,000 cases of laryngeal cancer are diagnosed each year and squamous cell carcinoma accounts for the vast majority of these tumors. Prior to 1991, total surgical removal of the larynx with postoperative radiation was the standard of care for advanced cancer. Since then, chemoradiation has become increasingly popular treatment because it can preserve the larynx.
How the Study Was Conducted: The authors evaluated survival outcomes for surgical vs. nonsurgical treatment for advanced laryngeal cancer. The authors used data from the Surveillance, Epidemiology and End Results (SEER) database for their study of 5,394 patients diagnosed with stage III or IV laryngeal squamous cell carcinoma between 1992 and 2009.
Results: Patients who had surgery had better 2-year and 5-year disease-specific survival (70 percent vs. 64 percent and 55 percent vs. 51 percent, respectively) and 2-year and 5-year overall survival (64 percent vs. 57 percent and 44 percent vs. 39 percent, respectively) than patients who did not under surgery. The use of nonsurgical treatment increased over time: 32 percent in the 1992 to 1997 patient group, 45 percent in the 1998 to 2003 group and 62 percent in the 2004 to 2009 group. The gap in survival between the two groups consistently narrowed over subsequent years. Patients who were diagnosed between 2004 and 2009 had better survival than those diagnosed earlier and this may be due to improvements in radiation and chemotherapy strategies.
Discussion: “Patients need to be made aware of the modest but significant survival disadvantage associated with nonsurgical therapy as part of the shared decision-making process during treatment selection.”
(JAMA Otolaryngol Head Neck Surg. Published online August 21, 2014. doi:10.1001/.jamaoto.2014.1671. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor’s Note: Please see article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.